Evofem Biosciences Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Evofem Biosciences prevailing Real Value cannot be determined due to lack of data. The current price of Evofem Biosciences is $0.0. Our model computes the value of Evofem Biosciences from reviewing the firm fundamentals such as Shares Owned By Insiders of 0.28 %, operating margin of (5.41) %, and Shares Outstanding of 121.22 M as well as analyzing its technical indicators and probability of bankruptcy. . In general, most investors advise obtaining undervalued instruments and abandoning overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Evofem Biosciences Total Value Analysis
Evofem Biosciences is currently forecasted to have valuation of 112.69 M with market capitalization of 6.41 M, debt of 125.74 M, and cash on hands of 19.89 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Evofem Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
112.69 M | 6.41 M | 125.74 M | 19.89 M |
Evofem Biosciences Investor Information
The company recorded a loss per share of 19.01. Evofem Biosciences last dividend was issued on the 18th of January 2018. The entity had 1:15 split on the 6th of May 2022. Based on the key indicators related to Evofem Biosciences' liquidity, profitability, solvency, and operating efficiency, Evofem Biosciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Evofem Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Evofem Biosciences has an asset utilization ratio of 19.39 percent. This suggests that the OTC Stock is making $0.19 for each dollar of assets. An increasing asset utilization means that Evofem Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Evofem Biosciences Ownership Allocation
Evofem Biosciences holds a total of 121.22 Million outstanding shares. Roughly 99.15 percent of Evofem Biosciences outstanding shares are held by general public with 0.28 (percent) owned by insiders and only 0.57 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Evofem Biosciences Profitability Analysis
The company reported the previous year's revenue of 8.24 M. Net Loss for the year was (205.19 M) with profit before overhead, payroll, taxes, and interest of 4.19 M.Evofem Biosciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Evofem Biosciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 125.2 M | |
| Retained Earnings | -860.7 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| CEOs Directory Screen CEOs from public companies around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |